Table 3 Baseline characteristics of propensity score-matched patients
IVIG (n = 40) | Acetaminophen (n = 40) | p | |||
|---|---|---|---|---|---|
n/mean | %/SD | n/mean | %/SD | ||
Female gender, n (%) | 10 | 25.0% | 8 | 20.0% | 0.59 |
Age (yr) | 66.7 | 15.6 | 67.1 | 16.4 | 0.91 |
Weight (kg) | 56.0 | 10.5 | 59.8 | 10.4 | 0.11 |
Comorbidities, n (%) | |||||
Hypertension | 16 | 40.0% | 18 | 45.0% | 0.65 |
Diabetes | 8 | 20.0% | 8 | 20.0% | 1.00 |
Chronic heart failure | 6 | 15.0% | 5 | 12.5% | 0.75 |
Infection site, n (%) | |||||
Pneumonia | 11 | 27.5% | 9 | 22.5% | 0.61 |
Bacteremia | 18 | 45.0% | 18 | 45.0% | 1.00 |
Intra-abdominal | 13 | 32.5% | 9 | 22.5% | 0.32 |
SOFA score (median/quartile) | 8 | (6–11.25) | 7 | (5.75–9.25) | 0.17 |
Organ support, n (%) | |||||
Invasive mechanical ventilation | 22 | 55.0% | 24 | 60.0% | 0.65 |
Renal replacement therapy | 16 | 40.0% | 17 | 42.5% | 0.82 |
Vasopressors | 17 | 42.5% | 15 | 37.5% | 0.65 |
Drugs, n (%) | |||||
Diuretics | 2 | 5.0% | 6 | 15.0% | 0.26 |
Nicardipine | 5 | 12.5% | 4 | 10.0% | 0.72 |
Plasma creatinine (mg/dL) | 1.97 | 1.57 | 1.85 | 1.98 | 0.77 |
Vital sign at IVIG/acetaminophen infusion | |||||
SBP (mmHg) | 114.4 | 30.4 | 119.4 | 22.4 | 0.41 |
MAP (mmHg) | 76.5 | 19.8 | 77.2 | 16.2 | 0.86 |
DBP (mmHg) | 56.7 | 16.6 | 56.1 | 13.6 | 0.84 |
HR (beats/min) | 99.6 | 21.0 | 104.1 | 22.2 | 0.36 |